Benny Sorensen - Jun 8, 2021 Form 4 Insider Report for Codiak BioSciences, Inc. (CDAKQ)

Role
Former SVP, Clinical Development
Signature
/s/ Yalonda Howze, by Power of Attorney for Benny Sorensen
Stock symbol
CDAKQ
Transactions as of
Jun 8, 2021
Transactions value $
-$190,942
Form type
4
Date filed
9/28/2021, 04:05 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDAKQ Common Stock Options Exercise $28.1K +8.53K $3.29* 8.53K Jun 8, 2021 Direct F1
transaction CDAKQ Common Stock Sale -$176K -6.89K -80.78% $25.57* 1.64K Jun 8, 2021 Direct F1, F2, F3
transaction CDAKQ Common Stock Sale -$42.7K -1.64K -100% $26.06* 0 Jun 8, 2021 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Stock Option (Right to Buy) Options Exercise $0 +8.53K +10.82% $0.00 87.4K Jun 8, 2021 Common Stock 8.53K $3.29 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were inadvertently reported late due to an administrative oversight related to communications of the transactions.
F2 The sales reported in this Form 4 were effected pursuant to a previously adopted Rule 10b5-1 trading plan.
F3 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $25.00 to $25.99 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $26.00 to $26.13 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F5 The shares underlying this option are fully vested.

Remarks:

Former SVP, Clinical Development